Please login to the form below

Not currently logged in


This page shows the latest QALY news and features for those working in and with pharma, biotech and healthcare.

ICER says Alnylam’s Onpattro should cost 90%-95% less

ICER says Alnylam’s Onpattro should cost 90%-95% less

Even at that level, ICER says the therapy far exceeds commonly accepted thresholds of $50, 000-$150, 000 per quality-adjusted life year (QALY) at $850, 000 per QALY gained, and

Latest news

More from news
Approximately 2 fully matching, plus 96 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...